By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



39, rue du Bois Chaland

Evry Cedex    91029  France
Phone: 33-1-608-72600 Fax: 33-1-608-61609



Company News
Ipsen (IPN.PA) And CNRS Create The "Archi-Pex" Joint Research And Innovation Lab, In Collaboration With The University Of Rennes 1 And CEA 11/20/2014 1:41:55 PM
Ipsen (IPN.PA) And Salk Institute for Biological Studies Renew Their Agreement For Discovery Research In Medical Sciences 11/18/2014 12:57:36 PM
Ipsen (IPN.PA) Announces FDA Approval Of A New Delivery Device For SomatulineĀ® DepotĀ® (Lanreotide) Injection 11/6/2014 11:06:28 AM
Otonomy, Inc. (OTIC) Obtains Rights To Gacyclidine Data From Ipsen (IPN.PA) To Support Development Of OTO-311 As A Treatment For Tinnitus 11/6/2014 11:02:22 AM
Ipsen (IPN.PA): Sales In The 3rd Quarter And First Nine Months Of 2014 10/29/2014 8:55:09 AM
Lexicon Pharmaceuticals, Inc. (LXRX), Ipsen (IPN.PA) Strike Licensing Deal Worth $145 Million 10/22/2014 6:00:45 AM
Ipsen (IPN.PA) Announces Positive Results From Phase III Clinical Study Of Decapeptyl® (triptorelin pamoate) 11.25 mg Administered By Subcutaneous Route To Prostate Cancer Patients 10/13/2014 11:02:52 AM
Aymeric Le Chatelier Joins Ipsen (IPN.PA) As Executive Vice President, Chief Financial Officer 10/10/2014 8:32:34 AM
Susheel Surpal Steps Down As Executive Vice President, Chief Financial Officer Of Ipsen (IPN.PA) To Pursue Other Opportunities 10/2/2014 10:39:22 AM
Ipsen (IPN.PA) Presents Preliminary Results Of Exploratory Proof-Of-Concept Study With Tasquinimod In Four Advanced Tumor Types At The ESMO 2014 Congress 9/29/2014 12:05:48 PM